Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
42.96M | 43.92M | 49.13M | 60.01M | 62.07M | Gross Profit |
31.79M | 32.75M | 36.47M | 44.99M | 45.08M | EBIT |
-1.30M | -1.67M | -270.00K | 1.57M | 669.00K | EBITDA |
-1.30M | -1.51M | -66.00K | 1.87M | 1.08M | Net Income Common Stockholders |
572.00K | 568.00K | 313.00K | 1.08M | 843.00K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
43.94M | 56.18M | 69.67M | 83.84M | 92.37M | Total Assets |
55.36M | 69.09M | 82.82M | 98.36M | 105.94M | Total Debt |
2.64M | 3.46M | 4.12M | 3.17M | 3.94M | Net Debt |
-10.89M | -52.71M | -65.54M | -80.68M | -88.43M | Total Liabilities |
22.49M | 27.49M | 32.67M | 38.87M | 38.24M | Stockholders Equity |
32.87M | 41.60M | 50.15M | 59.49M | 67.70M |
Cash Flow | Free Cash Flow | |||
-3.42M | -4.32M | -5.00M | 791.00K | 1.67M | Operating Cash Flow |
-3.37M | -4.28M | -4.85M | 1.02M | 1.89M | Investing Cash Flow |
-30.07M | -46.00K | -143.00K | -225.00K | -211.00K | Financing Cash Flow |
-9.21M | -9.21M | -9.14M | -9.14M | -9.14M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $5.44B | 20.90 | 22.95% | ― | 13.13% | 56.75% | |
70 Outperform | $217.74M | 29.16 | 4.98% | ― | 2.03% | -47.76% | |
66 Neutral | $836.90M | 3.31 | -31.74% | ― | -1.37% | 75.47% | |
66 Neutral | $481.69M | 11.63 | 7.76% | ― | -7.22% | -33.67% | |
59 Neutral | $11.20B | 10.09 | -1.41% | 3.96% | 1.31% | -16.95% | |
55 Neutral | $144.27M | 69.71 | 1.02% | ― | -43.80% | -97.89% | |
50 Neutral | $57.80M | 100.80 | 1.54% | 15.94% | -2.19% | 0.60% |
On April 1, 2025, Natural Health Trends Corp. announced the approval of phantom share awards under its Phantom Equity Plan. The awards, which include 124,850 shares for President Chris T. Sharng and 41,788 shares for CFO Timothy S. Davidson, have a two-year vesting period with conditions tied to the company’s financial performance and stock appreciation. These awards aim to incentivize key executives and directors, potentially impacting the company’s operational focus and aligning stakeholder interests with performance metrics.